首页> 外文期刊>Blood purification >Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series
【24h】

Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series

机译:脓毒症患者吸附过滤器氧化的连续肾脏替代疗法:案例系列

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Extracorporeal treatment may be useful during sepsis, but definitive recommendations are lacking. Aim of this study is to review retrospectively the medical records of septic patients submitted to continuous renal replacement therapy (CRRT) with the adsorbing membrane oXiris and evaluate (1) the safety of the device, (2) the cardiorenal response, and (3) the immunological response. Materials and Methods: The medical records of 60 septic patients submitted to CRRT with the membrane oXiris from April 2011 to December 2018 have been reviewed. The adsorbing membrane oXiris (R) (Baxter, IL, USA) was used through a Prisma plataform (Prismaflex-Baxter, IL, USA). At basal time (T0), at 24 h (T1), and at the end of the treatment (T2) were analyzed the clinical data, the cytokines, and the time course of endotoxin. Results: Sixty patients were included in the study. In total, 85% of patients had acute kidney injury (AKI). Every CRRT treatment was of 72 +/- 13 h, with the consumption of 3.2 +/- 1 filters. No AE events were reported. The main cardiorenal and respiratory parameters improved with a decrease of the noradrenaline dosage. Cytokines, procalcitonin, and endotoxin activity assay decreased too. SOFA total improved from 12.4 +/- 2 to 9 +/- 2. Conclusion: In sepsis/septic shock patients with AKI, CRRT with the adsorbing membrane oXiris may be safe and improves the cardiorenal-function and the clinical condition. The effect on cytokines and endotoxin may explain in part these results. A RCT is warranted to confirm these data. (c) 2019 The Author(s) Published by S. Karger AG, Basel
机译:背景:体外治疗可能在败血症期间有用,但缺乏明确的建议。本研究的目的是回顾性地审查脓毒症患者的病态,提交连续肾脏替代治疗(CRRT),吸附膜氧化乙醇,评价(1)器件的安全性,(2)内心深度反应和(3)免疫应答。材料与方法:从2011年4月到2018年4月从2011年4月到2018年4月提交给CRRT的60例脓毒症患者的病历。通过Prisma Plataform(Prismaflex-Baxter,IL,USA)使用吸附膜氧化(R)(Baxter,IL)。在基础时间(T0),在24小时(T1),在治疗结束时(T2)分析临床资料,细胞因子和内毒素的时间过程。结果:60例患者纳入研究。总共85%的患者患有急性肾损伤(AKI)。每次CRRT治疗为72 +/- 13小时,消耗3.2 +/- 1个过滤器。没有报告AE事件。主要的心肺和呼吸师参数随着去甲肾上腺素剂量的降低而改善。细胞因子,proCalcitonin和内毒素活性测定也降低了。沙发总量从12.4 +/- 2至9 +/- 2.结论:在败血症/脓毒症休克患者中,具有吸附膜氧化的CRRT可能是安全的,改善心血管功能和临床状况。对细胞因子和内毒素的影响可以部分解释这些结果。 RCT是保证才能确认这些数据。 (c)2019年由巴塞尔的S. Karger AG发布的提交人

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号